Southpaw Asset Management’s Nephros NEPH Stock Holding History

Southpaw Asset Management’s Portfolio NEPH Stock Details NEPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-73,810	Closed	-$601K	–	16
2019 Q3	$601K	Buy	+73,810	New	+$541K	0.54%	13

Other funds holding NEPH

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Southpaw Asset Management's NEPH Position: Q4 2019 in Review

Southpaw Asset Management sold out of Nephros (NEPH) in Q4 2019, closing a stake of 73,810 shares — an estimated $601K sold.

Southpaw Asset Management first reported a position in NEPH in Q3 2019 and held it in 1 quarter. The position peaked at $601K in Q3 2019. 13 funds tracked by Wall St. Rank hold NEPH as of Q4 2019.

Southpaw Asset Management reported no remaining Nephros position as of Q4 2019 after selling out during the quarter.
Southpaw Asset Management sold 73,810 Nephros shares in Q4 2019, an estimated $601K.
Southpaw Asset Management first reported a position in Nephros in Q3 2019 and held it in 1 quarter.
Southpaw Asset Management's Nephros position peaked at $601K in Q3 2019.
13 funds tracked by Wall St. Rank held Nephros as of Q4 2019.

Based on Southpaw Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.